Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation (AF) (Code-AF Trial)

Yonsei University20,000 enrolled

Overview

This study is prospective Cohort study which was performed in multicenter (General Hospital) in Korea. Inclusion criteria is all patients with atrial fibrillation who visit hospital. The purpose is to analyze complication, composite outcome (all cause mortality, hospitalization, the incidence of stroke, heart failure and cardiovascular event (MACE)) according to the 1) the use of anti-arrhythmic drugs (AADs), 2) use of medication for rate control (beta blocker, calcium channel blocker and digoxin) and 3) use of anticoagulation agents (warfarin, coumadin, an NOAC)

Study Type

OBSERVATIONAL

Enrollment

20,000

Conditions

Atrial Fibrillation

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with atrial fibrillation * patients with age more than 19 * patients who agree with study inclusion Exclusion Criteria: * patients who do not agree with study inclusion * patients with age less than 19 * Pregnancy, Breastfeeding

Locations (1)

Division of Cardiology, Yonsei University Health System, Yonsei University College of Medicine

Seoul, South Korea

Outcomes

Primary Outcomes

all cause mortality

Time frame: 3 years

number of hospitalization by heart failure

Time frame: 3 years

number of recurrent stroke

Time frame: 3 years

number of cardiovascular events

Time frame: 3 years